Bayer Execs Silent On Plans To Divest Material Sciences

28 Apr 2014

• By John Davis

The diversified German big pharma highlighted the sales growth of its five recently launched drugs in the first quarter, but declined to fuel M&A speculation surrounding its non-life sciences division.

Bayer AG executives refused to be drawn into discussions about divesting the company’s material sciences business as it reported strong first quarter sales and earnings growth on April 28, driven by its newly launched pharmaceutical products and despite substantial currency exchange rate headwinds stemming from the rise in the value of the euro against major currencies.

Divesting its plastics-based material sciences unit would focus the German diversified company on its life sciences businesses in pharmaceuticals, crop...

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

19 Sep 2024

• By Neena Brizmohun

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

16 Sep 2024

• By Nielsen Hobbs

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

04 Sep 2024

• By Nielsen Hobbs

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.